EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis

Celine Man Ying Li, Yoko Tomita, Bimala Dhakal, Runhao Li iD, Jun Li, Paul Drew, Timothy Price, Eric Smith, Guy J Maddern, Kevin Aaron Fenix iD

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2023-006764 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Celine Man Ying Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cytokine-Induced Killer Cells. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tour de Cure, The Hospital Research Foundation and Cancer Council SA Beat Cancer, The Hospital Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The number of clinical studies evaluating the benefit of cytokine-induced killer cell (CIK) therapy, an adoptive immunotherapy, for colorectal cancer (CRC) is increasing. In many of these trials, CIK therapy was coadministered with conventional cancer therapy. The aim of this review is to systematically assess the available literature, in which the majority were only in Chinese, on CIK therapy for the management of CRC using meta-analysis and to identify parameters associated with successful CIK therapy implementation.

Methods

Prospective and retrospective clinical studies which compared CIK therapy to non-CIK therapy in patients with CRC were searched for electronically on MEDLINE, Embase, China National Knowledge Infrastructure, and Wanfang Data databases. The clinical endpoints of overall survival (OS), progression-free survival (PFS), OS and PFS rates, overall response rate (ORR), and toxicity were meta-analyzed using HR and relative ratio (RR), and subgroup analyses were performed using chi-square (χ 2 ) test and I-squared (I 2 ) statistics for study design, disease stage, cotherapy type, and timing of administration.

Results

In total, 70 studies involving 6743 patients were analyzed. CIK therapy was favored over non-CIK therapy for OS (HR=0.59, 95% CI: 0.53 to 0.65), PFS (HR=0.55, 95% CI: 0.47 to 0.63), and ORR (RR=0.65, 95% CI: 0.57 to 0.74) without increasing toxicity (HR=0.59, 95% CI: 0.16 to 2.25). Subgroup analyses on OS and PFS by study design (randomized vs non-randomized study design), disease stage (Stage I–III vs Stage IV), cotreatment with dendritic cells (DCs) (CIK vs DC-CIK therapy), or timing of therapy administration (concurrent vs sequential with coadministered anticancer therapy) also showed that the clinical benefit of CIK therapy was robust in any subgroup analysis. Furthermore, cotreatment with DCs did not improve clinical outcomes over CIK therapy alone.

Conclusion

Compared with standard therapy, patients who received additional CIK cell therapy had favorable outcomes without increased toxicity, warranting further investigation into CIK therapy for the treatment of CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCytokine-Induced Killer CellsHumansImmunotherapy, AdoptiveProspective StudiesRetrospective StudiesClinical Trials as Topic

Stichwörter der Autor:innen

gastrointestinal neoplasmsimmunotherapy, adoptivereview

Autor:innen und Institutionen

  • Discipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
  • Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.
  • Medical Oncology, The Queen Elizabeth Hospital and The University of Adelaide, Adelaide, South Australia, Australia.
  • Urinary Surgery of Zhumadian Central Hospital, Zhumadian, Henan, China.
  • Discipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia kevin.fenix@adelaide.edu.au.

ORCID-Profile: Runhao Li, Kevin Aaron Fenix

Förderung

  • Tour de Cure
  • The Hospital Research Foundation and Cancer Council SA Beat Cancer
  • The Hospital Research Foundation
  • Schlumberger Foundation

Zitieren

APA

Li, C. M. Y., Tomita, Y., Dhakal, B., Li, R., Li, J., Drew, P., Price, T., Smith, E., Maddern, G. J., & Fenix, K. A. (2023). Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-006764

Vancouver

Li CMY, Tomita Y, Dhakal B, Li R, Li J, Drew P, et al. Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-006764

BibTeX
@article{Li2023,
  author = {Li, Celine Man Ying and Tomita, Yoko and Dhakal, Bimala and Li, Runhao and Li, Jun and Drew, Paul and Price, Timothy and Smith, Eric and Maddern, Guy J and Fenix, Kevin Aaron},
  title = {Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2023-006764}
}
Kostenlos starten →